Seelos Therapeutics (NASDAQ:SEEL) and Zoetis (NYSE:ZTS) Head-To-Head Contrast

Zoetis (NYSE:ZTS) and Seelos Therapeutics (NASDAQ:SEEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Profitability

This table compares Zoetis and Seelos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zoetis	26.29%	50.67%	17.88%
Seelos Therapeutics	203.13%	N/A	-431.47%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Zoetis and Seelos Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	0	0	9	1	3.10
Seelos Therapeutics	0	0	0	0	N/A

Zoetis presently has a consensus price target of $221.44, indicating a potential upside of 15.94%. Given Zoetis’ higher probable upside, equities analysts plainly believe Zoetis is more favorable than Seelos Therapeutics.

Volatility and Risk

Zoetis has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider & Institutional Ownership

92.8% of Zoetis shares are held by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 5.4% of Seelos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zoetis and Seelos Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$8.92 billion	9.78	$2.34 billion	$5.19	36.80
Seelos Therapeutics	$2.20 million	1.00	-$37.88 million	N/A	N/A

Zoetis has higher revenue and earnings than Seelos Therapeutics.

Summary

Zoetis beats Seelos Therapeutics on 9 of the 12 factors compared between the two stocks.

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.